Prostate Cancer Outcomes – Compare & Reduce Variation in  DKG - zertifizierten  Prostatakrebszentren

PEARL-Studie

MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse TUD-PEMAZA-068

An Epidemiological, Prospective Cohort Study to Generate Real-world Evidence in Patients with HR*/HER2- Advanced Breast Cancer Treated in the First-line Setting as per Current Standard of Care with an Endocrine-based Palbociclib Combination Therapy

An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC).

Prospektive nicht-interventionelle Studie zur Optimierung der onkologischen Therapie bei Patientinnen mit metastasiertem Mammakarzinom. Bewertung von Biomarker

Bei der Studie wird untersucht, ob es Biomarker gibt, die für die Prädiktion des progressionsfreien Überlebens geeignet sind.

PRESS -PAR: Early detection and PREvention of Symptomatic postSurgical hypoPARathyroidism after thyroid surgery

Evaluation der DIGA consilium care bei Patientinnen mit Her 2 positiven Brustkrebs während einer Chemotherapie in Kombination mit einer Her 2 zielgerichteten Antikörper Therapie

Real world experience of patients with metastatic castration resistant prostate Cancer treated with Olaparib+Abiraterone